These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [TBL] [Abstract][Full Text] [Related]
45. [Current issues in contraception]. Audebert AJ Contracept Fertil Sex (Paris); 1985 Feb; 13(2):467-73. PubMed ID: 12339971 [TBL] [Abstract][Full Text] [Related]
46. [Progress in combined oral contraception: gestodene, a third generation progestogen]. Belaïsch J Rev Fr Gynecol Obstet; 1989 May; 84(5):455-9. PubMed ID: 2740714 [TBL] [Abstract][Full Text] [Related]
47. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Odlind V; Milsom I; Persson I; Victor A Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300 [TBL] [Abstract][Full Text] [Related]
48. [The characteristics of triphasic estrogen-progesterone contraceptives and their theoretical indications]. Senèze J Rev Fr Gynecol Obstet; 1990 May; 85(5):301-5. PubMed ID: 2374864 [TBL] [Abstract][Full Text] [Related]
49. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Winkler UH; Sudik R Contraception; 2009 Jan; 79(1):15-23. PubMed ID: 19041436 [TBL] [Abstract][Full Text] [Related]
50. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850 [TBL] [Abstract][Full Text] [Related]
51. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800 [TBL] [Abstract][Full Text] [Related]
52. Classification and comparison of oral contraceptives containing new generation progestogens. Newton JR Hum Reprod Update; 1995 May; 1(3):231-63. PubMed ID: 9187941 [TBL] [Abstract][Full Text] [Related]
53. [Clinical analysis of a new triphasic estroprogestational combination with gestodene]. Mühe B; Vital MH Rev Fr Gynecol Obstet; 1988 Apr; 83(4):283-5. PubMed ID: 3393800 [TBL] [Abstract][Full Text] [Related]
54. The androgenicity of progestins. Darney PD Am J Med; 1995 Jan; 98(1A):104S-110S. PubMed ID: 7825629 [TBL] [Abstract][Full Text] [Related]
55. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Phillips A; Demarest K; Hahn DW; Wong F; McGuire JL Contraception; 1990 Apr; 41(4):399-410. PubMed ID: 2335104 [TBL] [Abstract][Full Text] [Related]
56. The androgenicity of progestational agents. Lobo RA Int J Fertil; 1988; 33 Suppl():6-12. PubMed ID: 2908040 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism. Stanczyk FZ Contraception; 1997 May; 55(5):273-82. PubMed ID: 9220223 [TBL] [Abstract][Full Text] [Related]
58. Marvelon--an OC with a new progestagen. Drug Ther Bull; 1984 Sep; 22(18):69-70. PubMed ID: 6236963 [No Abstract] [Full Text] [Related]